Search research articles
Contact Us
Filters
Showing results (21-30 of 35) with videos related to
Page
of 4
Sort By:
ESMO Open
|
February 11, 2026
Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer
A Grinshpun, D Dustin, M Cai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 29, 2019
A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma
E L Mayer, A DeMichele, H S Rugo, et al.
ESMO Open
|
June 12, 2026
Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based study
G Nader-Marta, L Ameye, D Martins-Branco, et al.
ESMO Open
|
June 8, 2026
Scalp cooling outcomes in patients receiving trastuzumab deruxtecan for metastatic breast cancer
E Salehi, X Chu, E L Mayer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancer
E L Mayer, D Trapani, S-E Kim, et al.
ESMO Open
|
July 6, 2026
TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancer
I Schlam, D Trapani, S-E Kim, et al.
ESMO Open
|
January 4, 2025
Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)
E Agostinetto, G Pfeiler, D Hlauschek, et al.
ESMO Open
|
July 27, 2025
Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer
R Jeselsohn, J Fu, Y Ren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 18, 2020
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker
E L Mayer, V Abramson, R Jankowitz, et al.
ESMO Open
|
July 27, 2025
Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study
C Corti, X Chu, P Exman, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 35) with videos related to
Sort By:
Page
of 4
ESMO Open
|
February 11, 2026
Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer
A Grinshpun, D Dustin, M Cai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 29, 2019
A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma
E L Mayer, A DeMichele, H S Rugo, et al.
ESMO Open
|
June 12, 2026
Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based study
G Nader-Marta, L Ameye, D Martins-Branco, et al.
ESMO Open
|
June 8, 2026
Scalp cooling outcomes in patients receiving trastuzumab deruxtecan for metastatic breast cancer
E Salehi, X Chu, E L Mayer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancer
E L Mayer, D Trapani, S-E Kim, et al.
ESMO Open
|
July 6, 2026
TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancer
I Schlam, D Trapani, S-E Kim, et al.
ESMO Open
|
January 4, 2025
Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)
E Agostinetto, G Pfeiler, D Hlauschek, et al.
ESMO Open
|
July 27, 2025
Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer
R Jeselsohn, J Fu, Y Ren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 18, 2020
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker
E L Mayer, V Abramson, R Jankowitz, et al.
ESMO Open
|
July 27, 2025
Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study
C Corti, X Chu, P Exman, et al.
Page
of 4